Moyamoya syndrome with ruptured aneurysm in α‑thalassemia: A case report

Zhu,Jiabin; Zhang,Mingwen; Sun,Yichun; Zhang,Xiaofeng

doi:10.3892/etm.2022.11494

Moyamoya syndrome with ruptured aneurysm in α‑thalassemia: A case report

Authors:
- Jiabin Zhu
- Mingwen Zhang
- Yichun Sun
- Xiaofeng Zhang
View Affiliations

Affiliations: Department of Neurosurgery, Affiliated Xiaolan Hospital, Southern Medical University, Xiaolan People's Hospital of Zhongshan, Zhongshan, Guangdong 528415, P.R. China, Department of Neurosurgery, Affiliated Xiaolan Hospital, Southern Medical University, Xiaolan People's Hospital of Zhongshan, Zhongshan, Guangdong 528415, P.R. China
Published online on: July 5, 2022 https://doi.org/10.3892/etm.2022.11494
Article Number: 556
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Moyamoya syndrome (MMS) refers to the moyamoya vascular disease associated with various systemic diseases and conditions, including sickle cell anemia, Fanconi anemia and iron deficiency anemia. However, the association between MMS and other hemoglobinopathies is less frequently observed. MMS, like moyamoya disease, is a cerebrovascular condition that is characterized by chronic progressive stenosis or occlusion at the ends of the bilateral internal carotid arteries, anterior cerebral arteries and the beginning of the middle cerebral arteries, and is secondary to the formation of an abnormal vascular network at the base of the skull. Patients with MMS are prone to thrombosis, aneurysm and bleeding. The present study reports the case of a 43‑year‑old man with α‑thalassemia who presented with moyamoya vessels with a ruptured aneurysm bleeding into the ventricle. α‑thalassemia is considered as an extremely rare but potential cause of MMS. Since MMS is a progressive disease, early diagnosis and treatment is vital to prevent the disease from worsening.

View Figures

View References

1	Yamani M, Obaid EF and Hemida AH: Moyamoya syndrome in a 32-year-old male with sickle cell anemia. Cureus. 12(e10001)2020.PubMed/NCBI View Article : Google Scholar
2	Al-Hawsawi ZM, Al-Zaid MA, Barnawi AI and Yassine SM: Fanconi anemia associated with moyamoya disease in Saudi Arabia. Saudi Med J. 36:233–235. 2015.PubMed/NCBI View Article : Google Scholar
3	Meena SS, Ramkumar TV, Sharma S, Aneja S and Kumar A: Moyamoya syndrome associated with severe iron deficiency anemia in a young child. Pediatr Hematol Oncol. 29:368–371. 2012.PubMed/NCBI View Article : Google Scholar
4	Das S, Dubey S, Acharya M, Chatterjee S, Lahiri D, Das G, Ray BK and Kraemer M: Thalassemia and moyamoya syndrome: Unfurling an intriguing association. J Neurol. 266:2838–2847. 2019.PubMed/NCBI View Article : Google Scholar
5	Bersano A, Guey S, Bedini G, Nava S, Hervé D, Vajkoczy P, Tatlisumak T, Sareela M, van der Zwan A, Klijn CJ, et al: Research progresses in understanding the pathophysiology of moyamoya disease. Cerebrovasc Dis. 41:105–118. 2016.PubMed/NCBI View Article : Google Scholar
6	Zhang L, Xing W and Zhang J: Recurrent transient ischemic attacks in a moyamoya syndrome patient with ultra-long imaging follow-up. Quant Imaging Med Surg. 12:2144–2152. 2022.PubMed/NCBI View Article : Google Scholar
7	Liu XJ, Zhang D, Wang S, Zhao YL, Teo M, Wang R, Cao Y, Ye X, Kang S and Zhao JZ: Clinical features and long-term outcomes of moyamoya disease: A single-center experience with 528 cases in China. J Neurosurg. 122:392–399. 2015.PubMed/NCBI View Article : Google Scholar
8	Shindo T, Ito M, Sugiyama T, Okuyama T, Kono M, Atsumi T and Fujimura M: Diagnostic value of vessel wall imaging to determine the timing of extracranial-intracranial bypass for moyamoya syndrome associated with active Sjögren's syndrome: A case report. J Neurol Surg A Cent Eur Neurosurg: Apr 22, 2022 (Epub ahead of print). doi: 10.1055/a-1832-3269.
9	Santoro JD, Lee S, Wang AC, Ho E, Nagesh D, Khoshnood M, Tanna R, Durazo-Arvizu RA, Manning MA, Skotko BG, et al: Increased autoimmunity in individuals with down syndrome and moyamoya disease. Front Neurol. 12(724969)2021.PubMed/NCBI View Article : Google Scholar
10	Nagel MA, Niemeyer CS and Bubak AN: Central nervous system infections produced by varicella zoster virus. Curr Opin Infect Dis. 33:273–278. 2020.PubMed/NCBI View Article : Google Scholar
11	Salih MA, Murshid WR, Al-Salman MM, Abdel-Gader AG, Al-Jarallah AA, Alorainy IA, Hassan HH, Kentab AY, Van Maldergem L, Othman SA, et al: Moyamoya syndrome as a risk factor for stroke in Saudi children. Novel and usual associations. Saudi Med J. 27 (Suppl 1):S69–S80. 2006.PubMed/NCBI
12	Piel FB and Weatherall DJ: The α-thalassemias. N Engl J Med. 371:1908–1916. 2014.PubMed/NCBI View Article : Google Scholar
13	Modell B and Darlison M: Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 86:480–487. 2008.PubMed/NCBI View Article : Google Scholar
14	Chui DH: Alpha-thalassaemia and population health in Southeast Asia. Ann Hum Biol. 32:123–130. 2005.PubMed/NCBI View Article : Google Scholar
15	Shang X, Peng Z, Ye Y, Asan Zhang X, Chen Y, Zhu B, Cai W, Chen S, Cai R, et al: Rapid targeted next-generation sequencing platform for molecular screening and clinical genotyping in subjects with hemoglobinopathies. EBioMedicin. 23:150–159. 2017.PubMed/NCBI View Article : Google Scholar
16	Berry JA, Cortez V, Toor H, Saini H and Siddiqi J: Moyamoya: An update and review. Cureus. 12(e10994)2020.PubMed/NCBI View Article : Google Scholar
17	Newman S, Boulter JH, Malcolm JG, Pradilla I and Pradilla G: Outcomes in patients with moyamoya syndrome and sickle cell disease: A systematic review. World Neurosurg. 135:165–170. 2020.PubMed/NCBI View Article : Google Scholar
18	Zhang H, Zheng L and Feng L: Epidemiology, diagnosis and treatment of moyamoya disease. Exp Ther Med. 17:1977–1984. 2019.PubMed/NCBI View Article : Google Scholar
19	Wu H, Huang Q, Yu Z and Zhong Z: Molecular analysis of alpha- and beta-thalassemia in Meizhou region and comparison of gene mutation spectrum with different regions of Southern China. J Clin Lab Anal. 35(e24105)2021.PubMed/NCBI View Article : Google Scholar
20	Huang Y, Long Y, Deng D, Liu Z, Liang H, Sun N, Xu Y, Lai Y and Cheng P: Alterations of anticoagulant proteins and soluble endothelial protein C receptor in thalassemia patients of Chinese origin. Thromb Res. 172:61–66. 2018.PubMed/NCBI View Article : Google Scholar
21	Gallagher PG: Disorders of erythrocyte hydration. Blood. 130:2699–2708. 2017.PubMed/NCBI View Article : Google Scholar
22	Litvinov RI and Weisel JW: Role of red blood cells in haemostasis and thrombosis. ISBT Sci Ser. 12:176–183. 2017.PubMed/NCBI View Article : Google Scholar
23	Bhattacharyya M, Kannan M, Chaudhry VP, Mahapatra M, Pati H and Saxena R: Hypercoagulable state in five thalassemia intermedia patients. Clin Appl Thromb Hemost. 13:422–427. 2007.PubMed/NCBI View Article : Google Scholar
24	Doctor PN, Choudhari A, Verma M and Merchant RH: Moyamoya syndrome in hemoglobin E-beta thalassemia: A rare presentation and association. J Postgrad Med. 64:240–242. 2018.PubMed/NCBI View Article : Google Scholar
25	Zahra A, Al-Abboh H, Habeeb Y and Adekile A: Moyamoya syndrome in a child with HbEβ-thalassemia. Clin Case Rep. 10(e05536)2022.PubMed/NCBI View Article : Google Scholar
26	Jang DK, Lee KS, Rha HK, Huh PW, Yang JH, Park IS, Ahn JG, Sung JH and Han YM: Bypass surgery versus medical treatment for symptomatic moyamoya disease in adults. J Neurosurg. 127:492–502. 2017.PubMed/NCBI View Article : Google Scholar
27	Zhao X, Wang X, Wang M, Meng Q and Wang C: Treatment strategies of ruptured intracranial aneurysms associated with moyamoya disease. Brit J Neurosurg. 35:209–215. 2021.PubMed/NCBI View Article : Google Scholar
28	Kuroda S and Houkin K: Bypass surgery for moyamoya disease: Concept and essence of sugical techniques. Neurol Med Chir (Tokyo). 52:287–294. 2012.PubMed/NCBI View Article : Google Scholar
29	Ren B, Zhang ZS, Liu WW, Bao XY, Li DS, Han C, Xian P, Zhao F, Wang H, Wang H and Duan L: Surgical outcomes following encephaloduroarteriosynangiosis in adult moyamoya disease associated with type 2 diabetes. J Neurosurg. 125:308–314. 2016.PubMed/NCBI View Article : Google Scholar
30	Miyamoto S, Yoshimoto T, Hashimoto N, Okada Y, Tsuji I, Tominaga T, Nakagawara J and Takahashi JC: JAM Trial Investigators. Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: Results of the Japan adult moyamoya trial. Stroke. 45:1415–1421. 2014.PubMed/NCBI View Article : Google Scholar
31	Wan M and Duan L: Recent progress in hemorrhagic moyamoya disease. Br J Neurosurg. 29:189–191. 2015.PubMed/NCBI View Article : Google Scholar
32	Han Q, Yao F, Zhang Z and Huang Y: Evaluation of revascularization in different Suzuki stages of ischemic moyamoya disease by whole-brain CT perfusion. Front Neurol. 12(683224)2021.PubMed/NCBI View Article : Google Scholar